StockData
CervoMed Inc. logo

CervoMed Inc. (CRVO) shareholders

CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$1.50−0.17 (-10.18%)

Close on Nov 17, 2026Market cap $22.68MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
11.6%
2M of 15M shares
Institutional holders
37
7 new, 5 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $3.00M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Boger Joshua S2,204,14320.00%13D (active) amendmentJun 11, 2026
Steven Boyd
Joint filing with Armistice Capital, LLC (9.53%)
1,592,8639.53%13G (passive)Jun 30, 2026
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (8.60%), Rajeev Shah (8.60%) and 1 more
1,266,1438.60%13G (passive) amendmentJun 30, 2026
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
1,026,9379.90%13G (passive) amendmentJun 30, 2025
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more
916,0639.90%13G (passive) amendmentDec 31, 2024
Woodline Partners LP688,9875.10%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CRVOValueChange% of portfolio
Woodline Partners LP688,9874.56%$2.14MNew0.01%
Vanguard Capital Management LLC316,2022.09%$980.23K–0.00%
Sabby Management, LLC248,8801.65%$771.53KNew0.70%
Geode Capital Management, LLC66,9230.44%$207.52K−7,4480.00%
BlackRock, Inc.53,8450.36%$166.92K+2,1850.00%
Byrne Asset Management LLC51,2500.34%$158.88K+36,5500.09%
Citizens Financial Group Inc/Ri37,4770.25%$116.18K–0.00%
Vanguard Fiduciary Trust Co36,1510.24%$112.07K–0.00%
Jane Street Group, LLC32,2310.21%$99.92K+13,9850.00%
Thompson Davis & Co., Inc.29,7500.20%$92.23K+19,7500.06%
Savvy Advisors, Inc.25,9220.17%$80.36K–0.00%
Virtu Financial LLC24,0930.16%$75.00KNew0.00%
State Street Corp20,5270.14%$63.63K–0.00%
Cetera Investment Advisers19,6220.13%$60.83K−7,7150.00%
Summit Financial, LLC18,1400.12%$56.23KNew0.00%
Russell Investments Group, Ltd.15,3630.10%$47.63K−7270.00%
Northern Trust Corp13,3180.09%$41.29K−16,7260.00%
Morgan Stanley12,6990.08%$39.37K−727,1930.00%
HighTower Advisors, LLC11,9190.08%$36.95K+6540.00%
FMR LLC10,5380.07%$32.67K−5020.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026372M11.6%7 / 98 / 51M1M
Q1 2026362M11.7%6 / 106 / 171M1M
Q4 2025482M14.6%9 / 1116 / 60M0M
Q3 2025452M14.1%13 / 716 / 120M0M
Q2 2025452M14.4%11 / 718 / 140M1M
Q1 2025482M15.1%11 / 1413 / 111M0M
Q4 2024491M9.8%15 / 1310 / 160M2M
Q3 2024504M23.2%16 / 1210 / 31M0M
Q2 2024383M22.8%20 / 73 / 21M0M
Q1 2024203M16.6%9 / 61 / 12M0M
Q4 2023120M2.2%2 / 32 / 20M0M
Q3 2023120M2.4%12 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

12 funds held CRVO in Q1 2026, 81% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CRVOValue% of fundAs of
Vanguard Total Stock Market Index Fund250,1741.65%$775.54K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund66,0280.44%$204.69K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund37,2410.25%$115.82K0.00%May 31, 2026
iShares Micro-Cap ETF19,5450.13%$60.59K0.00%Jun 30, 2026
Fidelity Total Market Index Fund9,0200.06%$28.05K0.00%May 31, 2026
Fidelity Series Total Market Index Fund8,9920.06%$27.97K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund7,4110.05%$23.05K0.00%May 31, 2026
Avantis U.S. Small Cap Equity ETF3,2810.02%$10.20K0.00%May 31, 2026
1290 VT Micro Cap Portfolio1,0680.01%$3.31K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
John J. AlamCEO & President, Director, 10% owner1,496,5789.90%Jun 10, 2026
Matthew WintonChief Commercial and Business15,0000.10%Oct 23, 2026
Rosch Mark DeEVP, RA and GA and PgM––Oct 23, 2026
Kelly BlackburnEVP, Clinical Development13,6740.09%Oct 23, 2026
William Robert ElderCFO, GC & Secretary12,5000.08%Feb 13, 2026
Robert Joseph Cobuzzi Jr.Chief Operating Officer1,6160.01%Feb 14, 2025
Joshua S. BogerDirector, 10% owner2,012,68213.31%Jun 15, 2026
Frank ZavrlDirector353,0092.33%Jun 10, 2026
Jane H. HollingsworthDirector9430.01%Jun 10, 2026
Jeffrey V. PoultonDirector––Jun 10, 2026
Marwan SabbaghDirector––Jun 10, 2026
David QuigleyDirector––Jun 10, 2026
Sylvie GregoireDirector, 10% owner1,496,5789.90%Jun 10, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Joshua S. Boger
Director, 10% owner
Jun 11, 2026Buy+955,414$3.14$3.00M1,795,865
Matthew Winton
Chief Commercial and Business
Nov 18, 2025Buy+1,500$7.95$11.93K15,000
William Robert Elder
CFO, GC & Secretary
Nov 18, 2025Buy+2,500$8.32$20.80K12,500
Matthew Winton
Chief Commercial and Business
Nov 17, 2025Buy+3,500$8.43$29.51K13,500
John J. Alam
CEO & President, Director, 10% owner
Nov 17, 2025Buy+10,793$8.46$91.31K12,500
John J. Alam
CEO & President, Director, 10% owner
Nov 17, 2025Buy+10,807$8.46$91.43K1,484,078
William Robert Elder
CFO, GC & Secretary
Nov 17, 2025Buy+1,000$8.45$8.45K10,000
Sylvie Gregoire
Director, 10% owner
Nov 17, 2025Buy+10,807$8.46$91.43K12,500
Sylvie Gregoire
Director, 10% owner
Nov 17, 2025Buy+10,793$8.46$91.31K1,484,078
Matthew Winton
Chief Commercial and Business
Nov 14, 2025Buy+10,000$7.57$75.70K10,000
John J. Alam
CEO & President, Director, 10% owner
Nov 14, 2025Buy+1,693$7.55$12.78K1,473,271
John J. Alam
CEO & President, Director, 10% owner
Nov 14, 2025Buy+1,707$7.57$12.92K1,707
Sylvie Gregoire
Director, 10% owner
Nov 14, 2025Buy+1,707$7.57$12.92K1,473,285
Sylvie Gregoire
Director, 10% owner
Nov 14, 2025Buy+1,693$7.55$12.78K1,693
John J. Alam
CEO & President, Director, 10% owner
Nov 13, 2025Buy+4,447$7.51$33.40K1,471,578
Sylvie Gregoire
Director, 10% owner
Nov 13, 2025Buy+4,447$7.51$33.40K1,471,578
John J. Alam
CEO & President, Director, 10% owner
Nov 12, 2025Buy+5,553$7.35$40.81K1,467,131
William Robert Elder
CFO, GC & Secretary
Nov 12, 2025Buy+3,500$7.44$26.04K9,000
Sylvie Gregoire
Director, 10% owner
Nov 12, 2025Buy+5,553$7.35$40.81K1,467,131
William Robert Elder
CFO, GC & Secretary
May 14, 2025Buy+4,233$8.46$35.81K5,500
William Robert Elder
CFO & GC
Aug 27, 2024Buy+1,000$18.16$18.16K1,267
Joshua S. Boger
Director, 10% owner
Feb 26, 2024Sale−36––840,451
Joshua S. Boger
Director, 10% owner
Feb 26, 2024Option exercise+495,995––840,487
Sylvie Gregoire
Director, 10% owner
Nov 9, 2023Gift−10,000––732,039
John J. Alam
CEO & President, Director, 10% owner
Nov 9, 2023Gift−12,500––729,539
Jane H. Hollingsworth
Director
Aug 31, 2023Option exercise+122––943
Jane H. Hollingsworth
Director
Aug 31, 2023Returned to company−45––898
Diana M. Lanchoney
Director
Jun 30, 2023Returned to company−85––294
Diana M. Lanchoney
Director
Jun 30, 2023Option exercise+232––379
Jane H. Hollingsworth
Director
May 31, 2023Returned to company−68––1,231
Jane H. Hollingsworth
Director
May 31, 2023Option exercise+183––1,299
Diana M. Lanchoney
Director
Mar 31, 2023Option exercise+232––232
Diana M. Lanchoney
Director
Mar 31, 2023Returned to company−85––147
Jane H. Hollingsworth
Director
Feb 28, 2023Returned to company−68––1,116
Jane H. Hollingsworth
Director
Feb 28, 2023Option exercise+183––1,184
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Jan 31, 2023Returned to company−121––1,616
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Jan 31, 2023Option exercise+327––1,737
Jane H. Hollingsworth
Director
Nov 30, 2022Option exercise+183––1,069
Jane H. Hollingsworth
Director
Nov 30, 2022Returned to company−68––1,001
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Oct 31, 2022Returned to company−121––1,410
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Oct 31, 2022Option exercise+327––1,531
Jane H. Hollingsworth
Director
Aug 31, 2022Option exercise+183––954
Jane H. Hollingsworth
Director
Aug 31, 2022Returned to company−67––886
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Aug 1, 2022Returned to company−121––1,204
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Aug 1, 2022Option exercise+327––1,325
Jane H. Hollingsworth
Director
May 31, 2022Option exercise+183––838
Jane H. Hollingsworth
Director
May 31, 2022Returned to company−67––771
Robert Joseph Cobuzzi Jr.
President & CEO, Director
May 2, 2022Option exercise+327––1,119
Robert Joseph Cobuzzi Jr.
President & CEO, Director
May 2, 2022Returned to company−121––998
William Robert Elder
GC & Secretary
Apr 18, 2022Conversion+100$25.00$2.50K400
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Apr 18, 2022Conversion+100$25.00$2.50K792
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Jan 31, 2022Returned to company−6,049––34,602
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Jan 31, 2022Option exercise+16,350––40,651
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Nov 1, 2021Option exercise+16,350––30,350
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Nov 1, 2021Returned to company−6,049––24,301
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Nov 1, 2021Option exercise+16,350––30,350
Jane H. Hollingsworth
Director
May 13, 2021Buy+32,786$0.61$20.00K32,786
William Robert Elder
GC & Secretary
Nov 17, 2020Buy+5,000$0.63$3.15K15,000
William Robert Elder
GC & Secretary
Nov 16, 2020Buy+10,000$0.67$6.70K10,000
Robert Joseph Cobuzzi Jr.
President & CEO, Director
Nov 16, 2020Buy+14,000$0.66$9.24K14,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.71%
1M shares short
Days to cover
4.7
At 0M shares a day
Change since last report
+0.4%
From 1M shares
Short volume, 20 days
58.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CervoMed's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,009 shares on Sep 3, 2026 over the last 90 days.

See a number that looks wrong?